Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | NNMT | P40261 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5670903 | 0.91 | OPRM1 (0.42) | OPRM1OPRK1OPRD1HDAC1PDE5A | |
| SCHEMBL4964601 | 0.87 | OPRM1 (0.57) | OPRM1OPRK1OPRD1HDAC1PDE5A | |
| SCHEMBL4963721 | 0.86 | SLC8A1 (0.39) | OPRM1OPRK1OPRD1HDAC1AURKA | |
| Hydrochloric Acid SCHEMBL4968080 | 0.86 | OPRM1 (0.56) | OPRM1OPRK1OPRD1HDAC1PDE5A | |
| SCHEMBL4965333 | 0.83 | OPRM1 (0.54) | OPRM1OPRK1OPRD1HDAC1PDE5A | |
| SCHEMBL14369648 | 0.83 | F2 (0.34) | OPRM1OPRK1OPRD1NNMT | |
| SCHEMBL4968119 | 0.82 | OPRM1 (0.40) | OPRM1OPRK1OPRD1HDAC1PDE5A | |
| SCHEMBL4966800 | 0.81 | OPRM1 (0.51) | OPRM1OPRK1OPRD1HDAC1AURKA | |
| SCHEMBL4964955 | 0.76 | F2 (0.35) | OPRM1OPRK1OPRD1HDAC1 | |
| SCHEMBL4964153 | 0.76 | OPRM1 (0.56) | OPRM1OPRK1OPRD1HDAC1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730140-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-06-25 | — | — | EP | claimed |
| US-7288543-B2 | For therapy or prophylaxis of obesity and related diseases including eating disorders (bulimia, anorexia nervosa, etc.), diabetes, diabetic complications, diabetic retinopathy, sexual/reproductive disorders, depression, anxiety, epileptic seizure, hypertension, cerebral hemorrhage | ELI LILLY AND COMPANY (US) | 2007-10-30 | — | — | US | claimed |
| US-20070179129-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY | 2007-08-02 | — | — | US | claimed |
| EP-1730140-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-1730140-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-06-25 | — | — | EP | disclosed |
| US-7288543-B2 | For therapy or prophylaxis of obesity and related diseases including eating disorders (bulimia, anorexia nervosa, etc.), diabetes, diabetic complications, diabetic retinopathy, sexual/reproductive disorders, depression, anxiety, epileptic seizure, hypertension, cerebral hemorrhage | ELI LILLY AND COMPANY (US) | 2007-10-30 | — | — | US | disclosed |
| US-7288543-B2 | For therapy or prophylaxis of obesity and related diseases including eating disorders (bulimia, anorexia nervosa, etc.), diabetes, diabetic complications, diabetic retinopathy, sexual/reproductive disorders, depression, anxiety, epileptic seizure, hypertension, cerebral hemorrhage | ELI LILLY AND COMPANY (US) | 2007-10-30 | — | — | US | disclosed |
| US-7288543-B2 | For therapy or prophylaxis of obesity and related diseases including eating disorders (bulimia, anorexia nervosa, etc.), diabetes, diabetic complications, diabetic retinopathy, sexual/reproductive disorders, depression, anxiety, epileptic seizure, hypertension, cerebral hemorrhage | ELI LILLY AND COMPANY (US) | 2007-10-30 | — | — | US | disclosed |
| US-20070179129-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY | 2007-08-02 | — | — | US | disclosed |
| US-20070179129-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY | 2007-08-02 | — | — | US | disclosed |
| US-20070179129-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179129-A1 | Opioid receptor antagonists | OPRK1, OPRM1, OPRL1 | OPRM1 2/4885OPRK1 1/4885OPRD1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.